EUVIMEDEUVIMED entdecken
Crossref

Changes in intestinal microbiota in pediatric cystic fibrosis patients after 6 months of elexacaftor‐tezacaftor‐ivacaftor therapy

Isabel Gutiérrez-Díaz, Jose R Gutiérrez-Martinez iD, Ruth García-Romero, Saioa Vicente-Santamaría, Agustin De La Mano-Hernández, Encarnación Torcuato-Rubio, Maria Garriga-Garcia, Carmen Martin-Fernández, Natalia Baston-Paz, Clara Simon-Bernaldo de Quiros, Juan J Díaz-Martín, Susana Delgado-Palacios und 1 weitere

Journal of Pediatric Gastroenterology and Nutrition · 2025

DOI: 10.1002/jpn3.70216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2025. Verfasst von Isabel Gutiérrez-Díaz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Biochemistry of Dairy Products, Instituto de Productos Lácteos de Asturias (IPLA), Consejo Superior de Investigaciones…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Gastrointestinal Microbiome, Aminophenols, Quinolones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Beca de Investigación Sira Carrasco de la Sociedad Española de Gastroenterología Hepatología y Nutrición Pediátrica (SEGHNP), Becas de Investigación fundación Ernesto Sánchez Villares, MCIN/AEI/10.13039/501100011033 and by European Union "NextGenerationEU/PRTR..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Cystic fibrosis (CF) is frequently associated with gastrointestinal problems, including intestinal microbiota dysbiosis. Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies, such as elexacaftor‐tezacaftor‐ivacaftor (ELX/TEZ/IVA), have demonstrated improvements in lung function, abdominal symptoms, and quality of life in patients with CF. However, the impact of these modulators on the intestinal microbiota in the pediatric population remains incompletely understood. The objective of this study was to characterize the changes in the intestinal microbiota of pediatric patients with CF after 6 months of treatment with ELX/TEZ/IVA.

Methods

Thirty‐one patients with CF, aged 6–18 years, were recruited. Stool samples were collected before the initiation of treatment and approximately 6 months thereafter. Microbiota analysis was performed using 16S rRNA gene amplicon sequencing. Statistical analyses were employed to evaluate changes in alpha and beta diversity and variations in the relative abundance of different bacterial taxa. Clinical variables such as concomitant use of azithromycin and probiotics were considered.

Results

After 6 months of treatment, no significant changes in the alpha diversity were observed. However, alterations in bacterial composition were detected. A decrease in the abundance of potentially pathogenic bacteria, such as Enterobacteriaceae members ( Escherichia/Shigella ) was observed. The abundance of genus Blautia increased. Differential analysis according to antibiotic and probiotic consumption revealed specific changes in microbiota composition.

Conclusions

ELX/TEZ/IVA therapy for 6 months induces changes in the intestinal microbiota composition of pediatric patients with CF, characterized by a reduction in potentially harmful bacteria and an increase in potentially beneficial bacteria. These findings suggest a modulation towards a healthier intestinal microbiota profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisGastrointestinal MicrobiomeAminophenolsQuinolonesBenzodioxolesIndolesPyridinesPyrazolesHumansChildAdolescentMaleFemaleDrug CombinationsChloride Channel AgonistsFecesTreatment OutcomeQuinolines

Stichwörter der Autor:innen

CFTR modulatorschildrengut dysbiosis

Substanzen

AminophenolsQuinolonesDrug CombinationsBenzodioxolesIndolesPyridinesPyrazolesChloride Channel Agonistselexacaftor, ivacaftor, tezacaftor drug combinationtezacaftor, ivacaftor drug combination

Autor:innen und Institutionen

  • Department of Microbiology and Biochemistry of Dairy Products, Instituto de Productos Lácteos de Asturias (IPLA), Consejo Superior de Investigaciones Científicas (CSIC), Villaviciosa, Spain.
  • MicroHealth Group, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
  • Pediatric Gastroenterology and Nutrition Section, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain.
  • Pediatric Gastroenterology and Nutrition, Hospital Materno-infantil Miguel Servet, Zaragoza, Spain.
  • Cystic Fibrosis Unit, Hospital Ramón y Cajal, Madrid, Spain.
  • Pediatric Gastroenterology and Nutrition, Hospital Universitario Infantil Niño Jesús, Madrid, Spain.

ORCID-Profile: Jose R Gutiérrez-Martinez

Förderung

  • Beca de Investigación Sira Carrasco de la Sociedad Española de Gastroenterología Hepatología y Nutrición Pediátrica (SEGHNP)
  • Becas de Investigación fundación Ernesto Sánchez Villares
  • MCIN/AEI/10.13039/501100011033 and by European Union "NextGenerationEU/PRTR.

Zitieren

APA

Gutiérrez-Díaz, I., Gutiérrez-Martinez, J. R., García-Romero, R., Vicente-Santamaría, S., De La Mano-Hernández, A., Torcuato-Rubio, E., Garriga-Garcia, M., Martin-Fernández, C., Baston-Paz, N., Simon-Bernaldo de Quiros, C., Díaz-Martín, J. J., Delgado-Palacios, S., & González-Jiménez, D. (2025). Changes in intestinal microbiota in pediatric cystic fibrosis patients after 6 months of elexacaftor‐tezacaftor‐ivacaftor therapy. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.70216

Vancouver

Gutiérrez-Díaz I, Gutiérrez-Martinez JR, García-Romero R, Vicente-Santamaría S, De La Mano-Hernández A, Torcuato-Rubio E, et al. Changes in intestinal microbiota in pediatric cystic fibrosis patients after 6 months of elexacaftor‐tezacaftor‐ivacaftor therapy. Journal of Pediatric Gastroenterology and Nutrition. 2025. doi:10.1002/jpn3.70216

BibTeX
@article{GutirrezDaz2025,
  author = {Gutiérrez-Díaz, Isabel and Gutiérrez-Martinez, Jose R and García-Romero, Ruth and Vicente-Santamaría, Saioa and De La Mano-Hernández, Agustin and Torcuato-Rubio, Encarnación and Garriga-Garcia, Maria and Martin-Fernández, Carmen and Baston-Paz, Natalia and Simon-Bernaldo de Quiros, Clara and Díaz-Martín, Juan J and Delgado-Palacios, Susana and González-Jiménez, David},
  title = {Changes in intestinal microbiota in pediatric cystic fibrosis patients after 6 months of elexacaftor‐tezacaftor‐ivacaftor therapy},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2025},
  doi = {10.1002/jpn3.70216}
}
Kostenlos starten →